ESR1 and breast cancer: Of note, its use in the treatment of ERα+ BC patients does not seem to be appropriated, both for the lack of functional VGSCs in this subset of tumors and for the SERM activity (either strong antagonist or weak agonist) exerted by PHT on ERα [96].